13.21
-0.09(-0.68%)
Currency In USD
| Previous Close | 13.3 |
| Open | 13.11 |
| Day High | 13.85 |
| Day Low | 13.07 |
| 52-Week High | 19.62 |
| 52-Week Low | 10.22 |
| Volume | 1.82M |
| Average Volume | 477,585 |
| Market Cap | 803.88M |
| PE | -3.94 |
| EPS | -3.35 |
| Moving Average 50 Days | 14.05 |
| Moving Average 200 Days | 13.16 |
| Change | -0.09 |
If you invested $1000 in Pliant Therapeutics, Inc. (PLRX) since IPO date, it would be worth $620.19 as of December 21, 2024 at a share price of $13.21. Whereas If you bought $1000 worth of Pliant Therapeutics, Inc. (PLRX) shares 3 years ago, it would be worth $863.96 as of December 21, 2024 at a share price of $13.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pliant Therapeutics to Participate in Upcoming Investor Events
GlobeNewswire Inc.
Nov 21, 2024 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
GlobeNewswire Inc.
Nov 18, 2024 11:00 PM GMT
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of no
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 9:05 PM GMT
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical bio